# Taysha Gene (TSHA) — News

TSHA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/tsha/news

## Recent headlines

- [Taysha Gene Therapies announces multiple encore presentations supporting TSHA-102 Rett syndrome clinical program at the 55th Child Neurology Society annual meeting](https://www.ainvest.com/news/taysha-gene-therapies-announces-multiple-encore-presentations-supporting-tsha-102-rett-syndrome-clinical-program-55th-child-neurology-society-annual-meeting-2610) — AInvest Wire, Oct 1, 2026
- [Taysha Gene Therapies Q2 EPS USD -0.13](https://www.ainvest.com/news/taysha-gene-therapies-q2-eps-usd-0-13-2608) — AInvest Wire, Aug 11, 2026
  Taysha Gene Therapies, Inc. (NASDAQ: TSHA) reported a net loss of $26.9 million for the second quarter of 2025, translating to an EPS loss of $0.09 . This represents an increase in the net loss compared to $20.9 million, or $0.09 per share, in the same period in 2024 . The company’s research and…
- [Taysha, Cytaleant sign commercial supply pact for TSHA-102](https://www.ainvest.com/news/taysha-cytaleant-sign-commercial-supply-pact-tsha-102-2608) — AInvest Wire, Aug 3, 2026
  Taysha Gene Therapies, Inc. (Nasdaq: TSHA) has entered into a commercial supply agreement with Cytaleant, a contract development and manufacturing organization (CDMO), to support the production of TSHA-102, its lead gene therapy candidate for Rett syndrome. The agreement is intended to facilitate…
- [Taysha Gene Therapies prices offer stock, pre-funded warranty](https://www.ainvest.com/news/taysha-gene-therapies-prices-offer-stock-pre-funded-warranty-2606) — AInvest Wire, Jun 25, 2026
- [Taysha Gene Therapies prices $32.5M stock offering at $6.00/shr](https://www.ainvest.com/news/taysha-gene-therapies-prices-32-5m-stock-offering-6-00-shr-2606) — AInvest Wire, Jun 25, 2026
  Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced the pricing of a public offering of 46,868,687 shares of its common stock at $2.75 per share, with an option for certain investors to receive pre-funded warrants to purchase 25,858,586 shares at $2.749 per warrant. The offering is expected to…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).